Cara Therapeutics, Inc. (CARA)
- Previous Close
0.6610 - Open
0.6600 - Bid 0.7362 x 100
- Ask 0.7604 x 200
- Day's Range
0.6501 - 0.7378 - 52 Week Range
0.5000 - 4.6700 - Volume
343,135 - Avg. Volume
653,209 - Market Cap (intraday)
39.921M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1900 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.23
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
www.caratherapeutics.comRecent News: CARA
Performance Overview: CARA
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CARA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CARA
Valuation Measures
Market Cap
40.24M
Enterprise Value
-54.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.90
Price/Book (mrq)
0.70
Enterprise Value/Revenue
-2.60
Enterprise Value/EBITDA
0.46
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.29%
Return on Equity (ttm)
-109.80%
Revenue (ttm)
20.97M
Net Income Avi to Common (ttm)
-118.51M
Diluted EPS (ttm)
-2.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
100.76M
Total Debt/Equity (mrq)
75.62%
Levered Free Cash Flow (ttm)
-52.53M
Research Analysis: CARA
Company Insights: CARA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CARA
CARA: What does Argus have to say about CARA?
CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetCARA: What does Argus have to say about CARA?
CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetCARA: What does Argus have to say about CARA?
CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetCARA: What does Argus have to say about CARA?
CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target